Independent Data Monitoring Committee has recommended to discontinue the STRENGTH trial as Epanova is unlikely to demonstrate a benefit. - AstraZeneca.
Related news and insights
Acasti Pharma Inc. focused on the research, development and commercialization of its prescription drug candidate CaPre (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (sHTG) (triglyceride blood levels from 500 mg/dL to 1500 mg/dL), announced top-line results for the Primary Endpoint (triglyceride reduction at 12 and 26 weeks) from its 278 patient Phase III TRILOGY 2 study evaluating the efficacy, safety and tolerability of CaPre in patients with severe hypertriglyceridemia.
HLS Therapeutics announced that final results with Vascepa (icosapent ethyl) in patients with coronary atherosclerosis, from the EVAPORATE Trial were presented at ESC Congress 2020.